Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next
Pfizer shares closed down 0.36% at $24.90 on Dec. 31 after the company raised U.S. list prices on about 80 drugs for 2026, including a 15% hike for COVID vaccine Comirnaty. TD Cowen reiterated a Hold rating with a $30 target. U.S. markets are closed Jan. 1 and reopen Jan. 2. Investors await Pfizer’s Feb. 3 earnings.